文献速递心脑血管急症重症综合管理与镇静镇痛

沙库巴曲缬沙坦治疗后N末端B型利钠肽原变化与射血分数降低心力衰竭患者心脏结构与功能的相关性

Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.
PubMed 文献 · JAMA · 2019-01-01
一句话结论HFrEF患者启动沙库巴曲缬沙坦后12个月NT-proBNP降低与左室射血分数、容积指数及左房容积指数改善呈弱但显著相关。

这项前瞻性、12个月、单组、开放标签研究纳入美国78个门诊中心的794例HFrEF患者,启动并调整沙库巴曲缬沙坦剂量。基线中位NT-proBNP为816 pg/mL,12个月降至455 pg/mL(P<.001)。12个月时log2-NT-proBNP变化与LVEF(r=-0.381)、LVEDVI(r=0.320)、LVESVI(r=0.405)、LAVI(r=0.263)和E/e'(r=0.269)变化均显著相关(P<.001)。LVEF从28.2%升至37.8%,LVEDVI和LVESVI均显著下降。作者认为观察到的逆重构可能为沙库巴曲缬沙坦在HFrEF中的效应提供机制解释。

要点

  • HFrEF患者启动沙库巴曲缬沙坦后12个月,中位NT-proBNP从816 pg/mL降至455 pg/mL(P<.001)。
  • 12个月时log2-NT-proBNP变化与LVEF变化呈负相关(r=-0.381),与LVESVI变化呈正相关(r=0.405),均P<.001。
  • 12个月LVEF从28.2%升至37.8%(差值9.4%,95%CI 8.8%–9.9%),LVEDVI从86.93降至74.15 mL/m2(差值-12.25 mL/m2)。
  • 最常见不良事件为低血压(17.6%)、头晕(16.8%)、高钾血症(13.2%)和肾功能恶化(12.3%)。

适用人群与场景

  • 美国78个门诊中心纳入的射血分数降低心力衰竭(HFrEF)患者,平均年龄65.1岁,女性226例(28.5%),平均LVEF 28.2%。

处置流程与药物剂量

  • 启动沙库巴曲缬沙坦并调整剂量(原文未写明具体起始剂量、目标剂量、给药途径和频次)。

研究设计与关键结果

  • 前瞻性、12个月、单组、开放标签研究,纳入794例HFrEF患者,654例(82.4%)完成研究;入组始于2016年10月25日,随访于2018年10月22日完成。
  • 基线中位NT-proBNP为816 pg/mL(IQR 332–1822),12个月为455 pg/mL(IQR 153–1090),差异P<.001。
  • 12个月log2-NT-proBNP变化与LVEF变化相关r=-0.381(IQR -0.448至-0.310),与LVEDVI变化相关r=0.320(IQR 0.246至0.391),与LVESVI变化相关r=0.405(IQR 0.335至0.470),与LAVI变化相关r=0.263(IQR 0.186至0.338),与E/e'变化相关r=0.269(IQR 0.182至0.353),均P<.001。
  • 12个月LVEF从28.2%升至37.8%(差值9.4%,95%CI 8.8%–9.9%),LVEDVI从86.93降至74.15 mL/m2(差值-12.25 mL/m2,IQR -12.92至-11.58),LVESVI从61.68降至45.46 mL/m2(差值-15.29 mL/m2,95%CI -16.03至-14.55),均P<.001;LAVI和E/e'亦显著下降。
  • 最常见不良事件为低血压(17.6%)、头晕(16.8%)、高钾血症(13.2%)和肾功能恶化(12.3%)。

证据类型、等级与局限

  • 证据类型:前瞻性、12个月、单组、开放标签研究(探索性研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,观察到的逆重构可能为沙库巴曲缬沙坦在HFrEF患者中的效应提供机制解释;该研究为探索性单组开放标签研究,NT-proBNP降低与心脏容积和功能指标改善呈弱但显著相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: In patients with heart failure and reduced ejection fraction (HFrEF), treatment with sacubitril-valsartan reduces N-terminal pro-b-type natriuretic peptide (NT-proBNP) concentrations. The effect of sacubitril-valsartan on cardiac remodeling is uncertain.

OBJECTIVE: To determine whether NT-proBNP changes in patients with HFrEF treated with sacubitril-valsartan correlate with changes in measures of cardiac volume and function.

DESIGN, SETTING, AND PARTICIPANTS: Prospective, 12-month, single-group, open-label study of patients with HFrEF enrolled in 78 outpatient sites in the United States. Sacubitril-valsartan was initiated and the dose adjusted. Enrollment commenced on October 25, 2016, and follow-up was completed on October 22, 2018.

EXPOSURES: NT-proBNP concentrations among patients treated with sacubitril-valsartan.

MAIN OUTCOMES AND MEASURES: The primary outcome was the correlation between changes in log2-NT-proBNP concentrations and left ventricular (LV) EF, LV end-diastolic volume index (LVEDVI), LV end-systolic volume index (LVESVI), left atrial volume index (LAVI), and ratio of early transmitral Doppler velocity/early diastolic annular velocity (E/e') at 12 months.

RESULTS: Among 794 patients (mean age, 65.1 years; 226 women [28.5%]; mean LVEF = 28.2%), 654 (82.4%) completed the study. The median NT-proBNP concentration at baseline was 816 pg/mL (interquartile range [IQR], 332-1822) and 455 pg/mL (IQR, 153-1090) at 12 months (difference, P < .001). At 12 months, the change in log2-NT-proBNP concentration was correlated with changes in LVEF (r = -0.381 [IQR, -0.448 to -0.310]; P < .001), LVEDVI (r = 0.320 [IQR, 0.246 to 0.391]; P < .001), LVESVI (r = 0.405 [IQR, 0.335 to 0.470]; P < .001), LAVI (r = 0.263 [IQR, 0.186 to 0.338]; P < .001), and E/e' (r = 0.269 [IQR, 0.182 to 0.353]; P < .001). At 12 months, LVEF increased from 28.2% to 37.8% (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001), while LVEDVI decreased from 86.93 to 74.15 mL/m2 (difference, -12.25 mL/m2 [IQR, -12.92 to -11.58]; P < .001) and LVESVI decreased from 61.68 to 45.46 mL/m2 (difference, -15.29 mL/m2 [95% CI, -16.03 to -14.55]; P < .001). LAVI and E/e' ratio also decreased significantly. The most frequent adverse events were hypotension (17.6%), dizziness (16.8%), hyperkalemia (13.2%), and worsening kidney function (12.3%).

CONCLUSIONS AND RELEVANCE: In this exploratory study of patients with HFrEF treated with sacubitril-valsartan, reduction in NT-proBNP concentration was weakly yet significantly correlated with improvements in markers of cardiac volume and function at 12 months. The observed reverse cardiac remodeling may provide a mechanistic explanation for the effects of sacubitril-valsartan in patients with HFrEF.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02887183.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Januzzi JL, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. 2019. PMID: 31475295. doi:10.1001/jama.2019.12821

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。